Jaguar Health Inc

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

JAGX$0.44+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

	Three Months Ended
	March 31,
(In thousands, except share and per share data) · 2025 · 2024
Product revenue, net	$	2,171	$	2,351
License revenue		43		—
Total revenue, net		2,214		2,351
Operating expenses
Cost of product revenue		515		430
Research and development		3,730		4,312
Sales and marketing		2,493		1,443
General and administrative		4,897		4,381
Total operating expenses		11,635		10,566
Loss from operations		(9,421)		(8,215)
Other income		112		234
Interest income (expense)		56		(611)
Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option		(1,343)		(2,021)
Gain on extinguishment of debt		—		1,245
Loss before income tax expense		(10,596)		(9,368)
Income tax expense		—		—
Net loss before equity in net loss of Joint venture		(10,596)		(9,368)
Equity in net loss of Joint venture
Net loss	$	(10,596)	$	(9,368)
Net loss attributable to noncontrolling interest	$	(132)	$	(142)
Net loss attributable to common stockholders	$	(10,464)	$	(9,226)
Net loss per share, basic and diluted	$	(16.70)	$	(87.12)
Weighted-average common stock outstanding, basic and diluted		626,644		105,895

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.